Advanced

Neuroprotective effects of the beta-carboline abecarnil studied in cultured cortical neurons and organotypic retinal cultures.

Ruscher, Karsten LU ; Rzeczinski, Stefan ; Thein, Elisabeth ; Freyer, Dorette ; Victorov, Ilya V ; Lam, Tim T and Dirnagl, Ulrich (2007) In Neuropharmacology 52(7). p.1488-1495
Abstract
Presently there is no neuroprotective pharmacological treatment of proven clinical safety and efficacy available. The purpose of this study was to investigate whether the ss-carboline, abecarnil (Abe), which has already passed clinical phase III trials in patients with anxiety disorders, is neuroprotective in in vitro models of cerebral ischemia or excitotoxicity. Abe (100 nM) protected cultured cortical neurons when applied 20 min before or 20 min after combined oxygen glucose deprivation (OGD). Furthermore, cultured cortical neurons were protected from NMDA excitotoxicity when Abe (100 nM) was administered 20 min before or concurrent with 100 mu M NMDA. In contrast, in adult rat organotypic retinal cultures, Abe failed to protect retinal... (More)
Presently there is no neuroprotective pharmacological treatment of proven clinical safety and efficacy available. The purpose of this study was to investigate whether the ss-carboline, abecarnil (Abe), which has already passed clinical phase III trials in patients with anxiety disorders, is neuroprotective in in vitro models of cerebral ischemia or excitotoxicity. Abe (100 nM) protected cultured cortical neurons when applied 20 min before or 20 min after combined oxygen glucose deprivation (OGD). Furthermore, cultured cortical neurons were protected from NMDA excitotoxicity when Abe (100 nM) was administered 20 min before or concurrent with 100 mu M NMDA. In contrast, in adult rat organotypic retinal cultures, Abe failed to protect retinal ganglion cells (RGCs) against glutamate (Glu) excitotoxicity. Thus, although our data demonstrate that Abe is a potential neuroprotectant in cultured neurons, the lack of effect in an organotypical model of Glu toxicity indicates that further study is required before Abe might be considered for human neuroprotection trials. 2007 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
organotypic retinal, neuroprotection, abecarnil, excitotoxicity, oxygen glucose deprivation, culture
in
Neuropharmacology
volume
52
issue
7
pages
1488 - 1495
publisher
Elsevier
external identifiers
  • wos:000247437200005
  • scopus:34248186156
  • pmid:17449066
ISSN
1873-7064
DOI
10.1016/j.neuropharm.2007.02.006
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Experimental Brain Research (0131000120), Laboratory for Experimental Brain Research (013041000)
id
f32b7f44-3ecd-4e6f-9ef3-034170f42634 (old id 167478)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17449066&dopt=Abstract
date added to LUP
2016-04-01 11:38:45
date last changed
2020-05-26 02:01:18
@article{f32b7f44-3ecd-4e6f-9ef3-034170f42634,
  abstract     = {Presently there is no neuroprotective pharmacological treatment of proven clinical safety and efficacy available. The purpose of this study was to investigate whether the ss-carboline, abecarnil (Abe), which has already passed clinical phase III trials in patients with anxiety disorders, is neuroprotective in in vitro models of cerebral ischemia or excitotoxicity. Abe (100 nM) protected cultured cortical neurons when applied 20 min before or 20 min after combined oxygen glucose deprivation (OGD). Furthermore, cultured cortical neurons were protected from NMDA excitotoxicity when Abe (100 nM) was administered 20 min before or concurrent with 100 mu M NMDA. In contrast, in adult rat organotypic retinal cultures, Abe failed to protect retinal ganglion cells (RGCs) against glutamate (Glu) excitotoxicity. Thus, although our data demonstrate that Abe is a potential neuroprotectant in cultured neurons, the lack of effect in an organotypical model of Glu toxicity indicates that further study is required before Abe might be considered for human neuroprotection trials. 2007 Elsevier Ltd. All rights reserved.},
  author       = {Ruscher, Karsten and Rzeczinski, Stefan and Thein, Elisabeth and Freyer, Dorette and Victorov, Ilya V and Lam, Tim T and Dirnagl, Ulrich},
  issn         = {1873-7064},
  language     = {eng},
  number       = {7},
  pages        = {1488--1495},
  publisher    = {Elsevier},
  series       = {Neuropharmacology},
  title        = {Neuroprotective effects of the beta-carboline abecarnil studied in cultured cortical neurons and organotypic retinal cultures.},
  url          = {http://dx.doi.org/10.1016/j.neuropharm.2007.02.006},
  doi          = {10.1016/j.neuropharm.2007.02.006},
  volume       = {52},
  year         = {2007},
}